NYSE: TMO · Diagnostics & Research

Thermo Fisher Scientific (TMO) fair value: undervalued or overvalued?

As of 14 Nov 2026, Faircurve's model values Thermo Fisher Scientific (TMO) at $687.16 a share. The stock last closed at $691.33, which puts the model's fair value 0.6% below the price. On the model's bands that reads as Fairly valued.

Revalued . Price is the close of 16 Nov 2026. Thermo Fisher Scientific Inc.

The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.

Model fair value$687.16midpoint of 2,000 simulations
Last close$691.33NYSE: TMO
Gap to fair value-0.6%fair value against price
Model verdictFairly valuedevidence grade: High

This week, in three parts

What happenedThe run of 14 Nov 2026 held the fair value at $687.16, within 1% of the run of 7 Nov 2026.

What the model makes of itThe price of $691.33 is 0.6% above it: Fairly valued, on a high evidence grade.

What's nextNext report on 4 Feb 2027. Options prices imply a move of about 10% either way over the next month. On the model's Earnings Momentum list since 29 Oct 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.

What price range does the model give TMO?

The calibrated range for TMO over 63 trading days is $617.59 to $778.29. It sits around the last close, and its width comes from the volatility that TMO's own options imply (34% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.

The model's own simulated range, from the 20th to the 80th percentile of its runs, is $566.39 to $819.53. In 46% of the simulations the fair value came out above the price the model ran on.

$447.54$1,032.66
Spread of the 2,000 simulated fair values. Solid line: the midpoint, $687.16. Dashed line: the last close, $691.33.

Faircurve Insights · 14 Nov 2026

Thermo Fisher Scientific Inc. is a global leader in scientific services. It offers life sciences solutions, advanced analytical instruments and specialised diagnostic products.

Faircurve's model put the fair value at $687.16 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $688.91, so the fair value moved -0.3%. The calibrated range over 63 trading days is $617.59 to $778.29, built around the price from the volatility the stock's own options imply. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is High, based on input completeness, the number of comparable companies and how closely they agree, and the width of outcomes. The grade does not say whether the fair value is right.

The business scores 53 out of 100 on quality against comparable companies. Stability is highest at 93, with five-year EBITDA margin downside volatility of 0.9 pts against a peer median of 4.0 pts. Balance sheet scores 38, with net debt to EBITDA of 3.19x against a peer median of 1.14x. Earnings quality scores 39, with FCF to net income of 1.07x against a peer median of 1.10x. The model compares it with Danaher Corporation, IDEXX Laboratories, Agilent Technologies, Waters Corporation, IQVIA Holdings, Mettler-Toledo International, Illumina and Labcorp Holdings.

Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.

The Global Pulse

Faircurve's note after each US session, in your inbox. No account needed.

When does TMO report earnings, and how has the stock reacted?

Thermo Fisher Scientific's next earnings report is scheduled for 4 Feb 2027. Companies can move their dates.

Options prices on 16 Nov 2026 imply a move of about 5.0% in either direction through the nearest expiry, about 10 days out. That is the size the market is pricing, not a direction. TMO's 30 day implied volatility works out to about 9.9% over one month.

Around its last 8 reports: what the options market priced, and what followed

Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across TMO's last 8 reports, ignoring direction, was 3.7%.

0%5%10%15%7.5%1.9%23 Apr '256.1%11.1%23 Jul '255.8%2.5%22 Oct '255.4%4.8%29 Jan '265.9%8.6%23 Apr '266.6%7.9%23 Jul '266.8%1.6%21 Oct '264.3%2.3%28 Oct '26priced before the reportthe move that followed
What the options market priced for each report, against the size of the move that followed. Priced: the move implied by options expiring after the report, on the last quote before it. Followed: the close before the report to the close after. Sizes only, no direction.

What the options market has priced for a month's move in TMO

0%5%10%15%28 Oct '26 report21 Oct '26 report23 Jul '26 report23 Apr '26 report29 Jan '26 report10% at 16 Nov '2614 Nov '2516 Nov '26
What the options market priced for a month's move (30-day implied volatility, scaled to one month). It read 7% on 14 Nov 2025, reached 11% on 16 Oct 2026 and reads 10% on 16 Nov 2026. The marks are report dates.

How does TMO score on business quality?

Thermo Fisher Scientific's overall quality score is 53 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.

FactorScore (0 to 100)Headline measurePeer median
ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend.488.5%ROIC8.9%
Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash).391.07xFCF / net income1.10x
Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes.633.9%Revenue growth, trailing3.8%
Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks.542.7%Net buybacks / market value2.3%
Balance sheetNet debt to EBITDA and interest coverage.383.19xNet debt / EBITDA1.14x
StabilityDownside volatility of the EBITDA margin over the last five years.930.9 ptsEBITDA margin downside volatility, 5y4.0 pts

How does TMO compare with similar companies?

The companies in diagnostics & research closest to Thermo Fisher Scientific in market value, each on the same model and the same date.

CompanyLast closeModel fair valueGapModel verdict
DHR Danaher Corporation$229.91$212.19-7.7%Fairly valued
IDXX IDEXX Laboratories, Inc.$700.65$568.18-18.9%Overvalued
A Agilent Technologies, Inc.$172.92$176.09+1.8%Fairly valued
WAT Waters Corporation$453.42$337.75-25.5%Overvalued
IQV IQVIA Holdings Inc.$264.73$335.69+26.8%Undervalued
MTD Mettler-Toledo International Inc.$1,727.26$1,679.36-2.8%Fairly valued
ILMN Illumina, Inc.$198.00$172.96-12.6%Fairly valued
LH Labcorp Holdings Inc.$372.46$465.68+25.0%Low evidence grade

What the comparable companies' multiples alone would give for TMO, the peer-implied price, is $668.02 a share on this run. The fair value weighs that against the company's own multiple.

All diagnostics & research stocks ranked by gap to fair value

Thermo Fisher Scientific at a glance

Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of.

Market value
$259.4B
Sector
Healthcare
Industry
Diagnostics & Research
Revenue expected, next twelve months
$50.2B
Consensus revenue growth, next fiscal year
+7.7%
Analysts with estimates
15
Beta to the US market
0.66
First valued by Faircurve
1 May 2026

At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. TMO was not among them.

How the fair value is worked out: the model prices Thermo Fisher Scientific on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.

What changed in the latest valuation?

On 7 Nov 2026 the model's fair value for TMO was $688.91. As of 14 Nov 2026 it is $687.16, a change of -0.3%. The model revalues every stock it covers each week, and again after an earnings report.

Questions about Thermo Fisher Scientific's valuation

Is Thermo Fisher Scientific stock undervalued or overvalued?

On Faircurve's model, TMO reads as Fairly valued as of 14 Nov 2026. The model's fair value is $687.16 a share against a last close of $691.33, a gap of -0.6%.

What is TMO's fair value?

$687.16 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $566.39 to $819.53.

What price range does the model give TMO?

$617.59 to $778.29 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.

When does Thermo Fisher Scientific report earnings next?

The next report is scheduled for 4 Feb 2027. Companies can move their dates.

How much has TMO moved on past earnings reports?

Across its last 8 reports the median two session move was 3.7%, ignoring direction. The largest was +11.1% around the report of 23 Jul 2025.

How confident is the model in this valuation?

The model's evidence grade for TMO is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.

The model's own ideas on TMO

The model has an idea open on TMO under Earnings Momentum since 29 Oct 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on TMO with their outcomes. A free account is enough.

Keep reading